

Ulcerative colitis and clinical course: Results of a 5-year (the IBSEN study)

Inflammatory Bowel Diseases

12, 543-550

DOI: [10.1097/01.mib.0000225339.91484.fc](https://doi.org/10.1097/01.mib.0000225339.91484.fc)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Developing a novel risk-scoring system for predicting relapse in patients with ulcerative colitis: A prospective cohort study. <i>Pakistan Journal of Medical Sciences</i> , 1969, 31, 1511-6.	0.3	1
2	Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 481-489.	0.9	340
3	Pediatric inflammatory bowel disease: Clinical and molecular genetics. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1430-1438.	0.9	66
4	Forecasting the recurrence of ulcerative colitis: Can U.C. the future?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 422-424.	0.9	2
5	What is the prognosis of ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S52-S53.	0.9	6
6	Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a caseâ€“control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 606-613.	1.9	22
7	Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2008, 135, 1114-1122.	0.6	784
8	Clinical course of ulcerative colitis. <i>Digestive and Liver Disease</i> , 2008, 40, S247-S252.	0.4	32
9	Natural History of Severe Ulcerative Colitis in a Community-Based Health Plan. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 999-1003.	2.4	52
10	Ulcerative proctitis: a review of pharmacotherapy and management. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 741-749.	0.9	29
11	Response to Dr. Ze-Zhou Song. <i>American Journal of Gastroenterology</i> , 2008, 103, 241-241.	0.2	0
12	Intestinal Macrophage/Epithelial Cell-Derived CCL11/Eotaxin-1 Mediates Eosinophil Recruitment and Function in Pediatric Ulcerative Colitis. <i>Journal of Immunology</i> , 2008, 181, 7390-7399.	0.4	146
13	What is the prognosis of ulcerative colitis?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S52-S53.	0.9	0
14	Clinical factors that impair health-related quality of life in ulcerative colitis patients vary with the disease duration. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 634-641.	0.8	11
16	Infliximab for the treatment of ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 219-229.	1.4	30
17	The Natural History of Pediatric Ulcerative Colitis: A Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 2080-2088.	0.2	273
18	Natural historyâ€“an optimistic message from Norway. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 387-388.	8.2	1
19	Pediatric Inflammatory Bowel Disease: Is It Different?. <i>Digestive Diseases</i> , 2009, 27, 212-214.	0.8	43

#	ARTICLE	IF	CITATIONS
20	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 176-181.	0.9	67
21	Pain and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 778-788.	0.9	224
22	Risk factors and characteristics of extent progression in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1320-1325.	0.9	63
23	Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 371-383.	0.2	267
24	Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 431-440.	0.6	628
25	Surgery in Ulcerative Colitis: Indication and Timing. <i>Digestive Diseases</i> , 2009, 27, 335-340.	0.8	81
26	Clinical Epidemiology of Ulcerative Colitis in Mexico. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 221-224.	1.1	42
27	Ulcerative colitis in the Tuzla region of Bosnia and Herzegovina between 1995 and 2006: epidemiological and clinical characteristics. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 346-353.	0.8	13
28	Need for standardization in population-based quality of life studies. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 525-536.	0.9	18
29	Ulcerative colitis in a Southern European country: A national perspective. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 822-829.	0.9	15
30	Genetic predictors of medically refractory ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1830-1840.	0.9	135
31	Infliximab for refractory ulcerative proctitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1178-1185.	1.9	42
32	HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. <i>Colorectal Disease</i> , 2010, 12, 1231-1235.	0.7	9
33	The Asia-Pacific consensus on ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 453-468.	1.4	134
34	Intestinal Protozoa Infections among Patients with Ulcerative Colitis: Prevalence and Impact on Clinical Disease Course. <i>Digestion</i> , 2010, 82, 18-23.	1.2	73
35	Is Inflammatory Bowel Disease More Severe when It Appears at Younger Ages?. <i>Digestion</i> , 2010, 81, 235-236.	1.2	0
36	Review: Current trends in inflammatory bowel disease: the natural history. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 77-86.	1.4	73
37	An Association Between Dietary Arachidonic Acid, Measured in Adipose Tissue, and Ulcerative Colitis. <i>Gastroenterology</i> , 2010, 139, 1912-1917.	0.6	83

#	ARTICLE	IF	CITATIONS
38	Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. <i>Gut</i> , 2010, 59, 49-54.	6.1	484
39	Epidemiology and Natural History of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2011, 140, 1785-1794.e4.	0.6	1,718
40	Literature review and recommendations for clinical application of Colon Capsule Endoscopy. <i>Digestive and Liver Disease</i> , 2011, 43, 251-258.	0.4	17
41	Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. <i>Human Immunology</i> , 2011, 72, 1029-1032.	1.2	33
42	Pediatric Inflammatory Bowel Disease (IBD): Phenotypic, Genetic and Therapeutic Differences between Early-Onset and Adult-Onset IBD. <i>Korean Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 14, 1.	0.2	13
43	Identifying predictors of low health-related quality of life among patients with inflammatory bowel disease: comparison between Crohn's disease and ulcerative colitis with disease duration. <i>Journal of Clinical Nursing</i> , 2011, 20, 1578-1587.	1.4	48
44	Genetics of childhood-onset inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 346-361.	0.9	63
45	Current misunderstandings in the management of ulcerative colitis. <i>Gut</i> , 2011, 60, 1294-1299.	6.1	39
46	Clinical application of the multigene analysis test in discriminating between ulcerative colitis and Crohn's disease: a retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 162-169.	0.6	10
47	Cost Utility of Inflammation-Targeted Therapy for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1143-1151.	2.4	16
48	Surgical and nonsurgical hospitalization rates and charges for patients with ulcerative colitis in Italy: A 10-year cohort study. <i>Digestive and Liver Disease</i> , 2012, 44, 369-374.	0.4	12
49	Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing. <i>American Journal of Gastroenterology</i> , 2012, 107, 1684-1692.	0.2	234
50	Surgical treatment of ulcerative colitis in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2012, 18, 1861.	1.4	42
51	Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2012, 4, 99.	0.4	40
52	Health-Related Quality of Life in Patients with Ulcerative Colitis After a 10-year Disease Course: Results from the IBSEN Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1540-1549.	0.9	92
53	Inflammatory bowel disease in Asia: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1266-1280.	1.4	283
54	Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 536-545.	0.9	109
55	Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 573-583.	0.9	116

#	ARTICLE	IF	CITATIONS
56	Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. <i>Irish Journal of Medical Science</i> , 2012, 181, 65-71.	0.8	7
57	Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. <i>Journal of Gastroenterology</i> , 2013, 48, 1006-1015.	2.3	32
58	Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. <i>Immunology Letters</i> , 2013, 149, 50-53.	1.1	13
59	The burden of inflammatory bowel disease in Europe. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 322-337.	0.6	781
60	Clinical Course of Intestinal Behçet's Disease During the First Five Years. <i>Digestive Diseases and Sciences</i> , 2013, 58, 496-503.	1.1	51
61	Personalizing therapy for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 549-558.	1.4	10
62	Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies. <i>Gastroenterology</i> , 2013, 145, 996-1006.	0.6	670
64	Immunosuppression After Liver Transplantation for Primary Sclerosing Cholangitis Influences Activity of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 517-523.	2.4	57
65	Review article: strategies for the management of chronic unremitting ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 77-97.	1.9	34
66	Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study. <i>Gastroenterology</i> , 2013, 145, 158-165.e2.	0.6	633
67	Prevalence of Corticosteroids Use and Disease Course After Initial Steroid Exposure in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2963-2969.	1.1	35
68	Pediatric inflammatory bowel disease: Can patterns in Asia shed some light?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 387-389.	1.4	1
69	Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 264-273.	1.9	61
70	First Prospective, Population-Based Inflammatory Bowel Disease Incidence Study in Mainland of China. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	0.9	94
71	Phenotype of Inflammatory Bowel Disease at Diagnosis in the Netherlands. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2215-2222.	0.9	41
72	Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 576-581.	0.9	54
73	Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis. <i>Disease Markers</i> , 2014, 2014, 1-7.	0.6	22
74	Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 69-76.	1.9	55

#	ARTICLE	IF	CITATIONS
75	Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003â€“2011â€”A Danish population-based cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1675-1683.	0.6	54
76	Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study. <i>Clinical and Experimental Immunology</i> , 2014, 177, 64-75.	1.1	58
77	Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe longâ€”term course of the disease â€” a nationwide study of 1035 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 374-381.	1.9	36
78	Standardized Recording of Parameters Related to the Natural History of Inflammatory Bowel Disease: From Montreal to Paris. <i>Digestive Diseases</i> , 2014, 32, 337-344.	0.8	13
79	What Have We Learnt about the Role of the Environment and Natural Course of IBD in the New Millennium? 20-Year Follow-Up of the IBSEN Cohort. <i>Digestive Diseases</i> , 2014, 32, 2-9.	0.8	9
80	Drug Therapies for Ulcerative Proctitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2157-2178.	0.9	21
81	The Burden of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 545-552.	0.9	106
82	An Overview of the Natural History of Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2014, 32, 320-327.	0.8	44
83	Refractory Distal Ulcerative Colitis: Is Proctocolectomy Always Necessary?. <i>Digestive Diseases</i> , 2014, 32, 110-115.	0.8	0
84	Proximal disease extension and related predicting factors in ulcerative proctitis. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 177-183.	0.6	47
85	Risk Matrix for Prediction of Advanced Disease in a Population-based Study of Patients with Crohn's Disease (the IBSEN Study). <i>Inflammatory Bowel Diseases</i> , 2014, 20, 60-68.	0.9	46
86	Epidemiology of inflammatory bowel disease: Focus on Asia. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 363-372.	1.0	120
87	Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals. <i>Molecular Biology Reports</i> , 2014, 41, 2171-2176.	1.0	13
88	Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. <i>Gut</i> , 2014, 63, 423-432.	6.1	282
89	Editorial: early corticosteroids in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 727-727.	1.9	2
90	Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1523-1528.	0.6	17
91	Ulcerative proctitis: an update on the pharmacotherapy and management. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1565-1573.	0.9	18
92	DOP044 Patient education in a 14 month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S36.	0.6	5

#	ARTICLE	IF	CITATIONS
93	Disease severity in familial cases of IBD. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 234-239.	0.6	22
94	Presentation and Progression of Childhood-Onset Inflammatory Bowel Disease in Northern Stockholm County. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1098-1108.	0.9	42
95	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	11
96	The role of endoscopy in inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2015, 16, 689-698.	0.7	5
97	Very Early-onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1166-1175.	0.9	82
98	Endoscopic Evaluation of Surgically Altered Bowel in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	13
99	Patterns and Predictors of Long-term Nonuse of Medical Therapy Among Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1615-1622.	0.9	13
100	Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. <i>United European Gastroenterology Journal</i> , 2015, 3, 72-79.	1.6	45
101	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2015, 25, 67-71.	1.7	21
102	Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1456-1462.	0.6	44
103	Health-related Quality of Life in Inflammatory Bowel Disease in a European-wide Population-based Cohort 10 Years After Diagnosis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 337-344.	0.9	59
104	Inflammatory Bowel Disease. <i>Surgical Clinics of North America</i> , 2015, 95, 1105-1122.	0.5	148
105	Can narrow-band imaging of Peyer's patches predict the recurrence of ulcerative colitis?. <i>Intestinal Research</i> , 2016, 14, 295.	1.0	0
106	Inflammatory Bowel Disease: Crohn's disease and ulcerative colitis. <i>Deutsches Ärzteblatt International</i> , 2016, 113, 72-82.	0.6	111
107	Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1679-1687.	0.9	35
108	Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls. <i>BMC Gastroenterology</i> , 2016, 16, 139.	0.8	2
109	Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. <i>Immunologic Research</i> , 2016, 64, 901-907.	1.3	23
110	Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. <i>Immunology Letters</i> , 2016, 172, 79-83.	1.1	24

#	ARTICLE	IF	CITATIONS
111	Clinical Aspects of Idiopathic Inflammatory Bowel Disease: A Review for Pathologists. Archives of Pathology and Laboratory Medicine, 2016, 140, 413-428.	1.2	20
112	Evaluation of pouches and stomas. Techniques in Gastrointestinal Endoscopy, 2016, 18, 152-157.	0.3	1
113	Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. Journal of Crohn's and Colitis, 2017, 11, jjw193.	0.6	28
114	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. Inflammatory Bowel Diseases, 2016, 22, 919-924.	0.9	11
115	Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009*. Scandinavian Journal of Gastroenterology, 2016, 51, 1339-1344.	0.6	27
116	Mortality and Causes of Death in Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 141-145.	0.9	14
117	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.4	34
118	Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 828-836.	0.6	42
119	Treat to Target in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2016, 14, 61-72.	0.3	29
120	Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. Gastroenterology, 2016, 150, 86-95.e3.	0.6	94
121	The Natural History of Inflammatory Bowel Disease. , 2017, , 301-309.		0
122	Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. Journal of Crohn's and Colitis, 2017, 11, 1052-1062.	0.6	17
123	Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. Scientific Reports, 2017, 7, 46693.	1.6	8
124	Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1481-1492.	1.9	55
125	Patient-Reported Outcomes of Quality of Life, Functioning, and GI/Psychiatric Symptom Severity in Patients with Inflammatory Bowel Disease (IBD). Inflammatory Bowel Diseases, 2017, 23, 798-803.	0.9	56
126	A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 991-997.	0.9	10
127	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut, 2017, 66, 1912-1917.	6.1	24
128	Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United European Gastroenterology Journal, 2017, 5, 554-562.	1.6	27

#	ARTICLE	IF	CITATIONS
129	Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. <i>Seminars in Pediatric Surgery</i> , 2017, 26, 349-355.	0.5	224
130	Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 351-358.	0.6	52
131	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017, 49, 17-23.	0.4	35
132	The Disease Burden and Clinical Characteristics of Inflammatory Bowel Disease in the Chinese Population: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 238.	1.2	62
133	Visceral Inflammation and Immune Activation Stress the Brain. <i>Frontiers in Immunology</i> , 2017, 8, 1613.	2.2	50
134	Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 662-669.	0.6	56
135	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 811-818.	0.6	88
136	Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 605-614.	1.9	57
137	Efficacy of Home Telemonitoring versus Conventional Follow-up: A Randomized Controlled Trial among Teenagers with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 432-441.	0.6	46
138	Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2291-2302.	0.9	22
139	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. <i>Journal of Gastroenterology</i> , 2018, 53, 494-506.	2.3	20
140	Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 152-157.	0.6	16
141	Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 755-772.	1.0	34
142	The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	1.4	13
143	Endoscopic Evaluation of Surgically Altered Bowel in Patients With Inflammatory Bowel Diseases. , 2018, , 141-159.		0
144	Refractory ulcerative proctitis: How to treat it?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 49-57.	1.0	24
145	Biological therapy and surgery rates in inflammatory bowel diseases " Data analysis of almost 1000 patients from a Hungarian tertiary IBD center. <i>PLoS ONE</i> , 2018, 13, e0200824.	1.1	6
146	Relapse Prevention in Ulcerative Colitis by Plant-Based Diet Through Educational Hospitalization: A Single-Group Trial. , 2018, 22, 17-167.		19

#	ARTICLE	IF	CITATIONS
147	Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. <i>Journal of Inflammation</i> , 2018, 15, 13.	1.5	19
148	Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)" An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 1267-1275.	0.2	4
149	Surgery in ulcerative colitis: When? How?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 71-78.	1.0	56
150	A systems pharmacology model for inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0192949.	1.1	27
151	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 163-171.	0.9	6
153	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Cut</i> , 2019, 68, s1-s106.	6.1	1,353
154	Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 80-85.	0.8	1
155	Genetic Studies of Inflammatory Bowel Disease-Focusing on Asian Patients. <i>Cells</i> , 2019, 8, 404.	1.8	52
156	Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial. , 2019, 23, .		26
157	Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1301-1313.	1.9	30
158	Very Early Onset Inflammatory Bowel Disease (VEOIBD). , 2019, , 383-404.		0
159	Time to include patients with ulcerative proctitis in clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 900-902.	3.7	5
160	Big data in IBD: a look into the future. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 312-321.	8.2	103
161	Appendectomy for Therapy-Refractory Ulcerative Colitis Results in Pathological Improvement of Colonic Inflammation: Short-Term Results of the PASSION Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 165-171.	0.6	34
162	Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. <i>BMC Gastroenterology</i> , 2020, 20, 321.	0.8	8
163	Surgical Management of Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 753-768.	1.0	9
164	Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2080-2087.	1.4	11
165	Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	1.4	23

#	ARTICLE	IF	CITATIONS
166	Disease Activity Patterns in the First 5 Years After Diagnosis in Children With Ulcerative Colitis: A Population-Based Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 367-374.	0.6	5
167	Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12962.	1.3	12
168	Dental pulp stem cells overexpressing hepatocyte growth factor facilitate the repair of DSS-induced ulcerative colitis. <i>Stem Cell Research and Therapy</i> , 2021, 12, 30.	2.4	14
169	Predicting Outcome in Acute Severe Colitis—Controversies in Clinical Practice in 2021. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1211-1221.	0.6	17
170	The Burden of Inflammatory Bowel Disease in Europe in 2020. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1573-1587.	0.6	160
171	Predicting Therapeutic Response in Pediatric Ulcerative Colitis—A Journey Towards Precision Medicine. <i>Frontiers in Pediatrics</i> , 2021, 9, 634739.	0.9	7
172	Tasas de colectomía en colitis ulcerosa 15 años después del diagnóstico. Datos de la cohorte Navarra 2001-2003. <i>Gastroenterología Y Hepatología</i> , 2022, 45, 1-8.	0.2	4
173	Drug development for ulcerative proctitis: current concepts. <i>Gut</i> , 2021, 70, 1203-1209.	6.1	7
174	Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. <i>Meditinskiy Sovet</i> , 2021, , 113-123.	0.1	3
175	ECCO Topical Review: Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1605-1620.	0.6	16
177	Ulcerative Proctitis and Anorectal Crohn's Disease. , 2019, , 531-554.		1
178	Moderate-to-severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 569-573.	0.9	3
179	Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran. <i>Annals of Colorectal Research</i> , 2016, 4, .	0.1	5
180	Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. <i>Al'manah Klinicheskoy Meditsiny</i> , 2018, 46, 445-463.	0.2	41
181	Framework for assessing quality of care for inflammatory bowel disease in Sweden. <i>World Journal of Gastroenterology</i> , 2012, 18, 1085.	1.4	17
182	Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 11525.	1.4	102
183	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017, 23, 3890.	1.4	28
184	Albumin as a prognostic marker for ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 8008-8016.	1.4	50

#	ARTICLE	IF	CITATIONS
185	Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 235.	0.6	29
186	Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 21-24.	0.4	2
187	Clinical course and predictors of total colectomy in ulcerative colitis; a referral center experience from Turkey. <i>Turkish Journal of Gastroenterology</i> , 2015, 26, 25-30.	0.4	8
188	Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. <i>Iranian Red Crescent Medical Journal</i> , 2015, 17, e22796.	0.5	11
189	Biologicals in treatment of acute ulcerative colitis. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2015, 36, 80-85.	0.0	9
190	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	0.6	120
191	Statistical Analysis of The Risk Factor of Colitic Cancer in UC Patients using Tree Model. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2010, 63, 407-414.	0.1	0
192	The Incidence of Proximal Extension of Ulcerative Proctitis in Japan and Factors Related to Proximal Extension. <i>The Showa University Journal of Medical Sciences</i> , 2011, 23, 11-21.	0.1	0
193	Chronisch-entzündliche Darmerkrankungen (CED). , 2013, , 333-361.		0
194	The Natural History of Ulcerative Colitis. , 2014, , 23-30.		0
195	What Happens If I Do Nothing for My Ulcerative Colitis? The Natural History of Untreated Ulcerative Colitis. , 2015, , 41-51.		0
196	Surgical outcomes of Korean ulcerative colitis patients with and without colitis-associated cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 3547.	1.4	5
198	Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 969-979.	0.6	29
199	State-of-the-Art Lecture: Future therapies in inflammatory bowel diseases. , 0, , 232-242.		0
200	Endoscopic and histologic findings in pediatric inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2010, 6, 174-80.	0.2	9
201	Predictors of aggressive inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2011, 7, 652-9.	0.2	31
202	Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. <i>Annals of Gastroenterology</i> , 2013, 26, 243-248.	0.4	30
203	Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5551.	1.0	9

#	ARTICLE	IF	CITATIONS
204	Chronisch entzündliche Darmerkrankungen: Tipps für eine differenzierte Biologika-Auswahl. , 0, , .		0
205	What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?. <i>Gastroenterology</i> , 2022, 162, 1396-1408.	0.6	49
206	When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100071.	1.7	1
207	Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort. <i>Gastroenterology Y Hepatologia (English Edition)</i> , 2022, 45, 1-8.	0.0	0
208	Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center. , 2022, 33, 320-328.		0
209	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, <sc>OCTAVE</sc> open. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	1.9	5
210	Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 936-941.	0.6	7
211	A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. <i>Crohn's & Colitis</i> 360, 2022, 4, .	0.5	2
215	Enflamatuvar barsak hastalarında olan hastalarda klinik özellikler, tedavi seçenekleri ve komplikasyonların değerlendirilmesi. <i>Family Practice and Palliative Care</i> , 0, , 64-70.	0.2	0
216	Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10-year follow up study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
217	Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
218	The Full Picture of Ulcerative Colitis: The Burden, the Patient, the Treatment. <i>European Medical Journal Gastroenterology</i> , 0, , 58-64.	0.0	0
219	Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn's Disease, Ulcerative Colitis) in the Russia. The Primary Results of the Analysis of the National Register. <i>Koloproktologia</i> , 2023, 22, 65-82.	0.1	5
220	Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center. <i>Patient Preference and Adherence</i> , 0, Volume 17, 807-816.	0.8	2
221	Krankheitsbewältigung bei Colitis ulcerosa: Die therapeutischen Ziele für die Zukunft bei der Behandlung von Colitis ulcerosa. <i>Karger Kompass Autoimmun</i> , 2023, 5, 61-66.	0.0	0